NCT05578222 is a Phase 2 clinical trial of Pembrolizumab in NSCLC With COPD, sponsored by Tianjin Chest Hospital.

Who is sponsoring NCT05578222?

NCT05578222 is sponsored by Tianjin Chest Hospital.

What drugs are being tested in NCT05578222?

Interventions in NCT05578222: Pembrolizumab.

What condition does NCT05578222 study?

NCT05578222 studies NSCLC With COPD.

Is NCT05578222 still recruiting?

NCT05578222 is currently status unknown. Last updated 13 October 2022.

Last reviewed 2022-10-13 · How we verify

NCT05578222

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

Status unknown Phase 2 Last updated 13 October 2022

What this trial tests

Phase 2 trial testing Pembrolizumab in NSCLC With COPD in 30 participants. Status unknown.

Timeline

10 October 2022

Primary endpoint
12 December 2023

12 December 2024

Quick facts

Lead sponsor	Tianjin Chest Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	10 October 2022
Primary completion	12 December 2023
Estimated completion	12 December 2024
Sites	1 location across China

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

NSCLC With COPD — all drugs for NSCLC With COPD →

Sponsor

Tianjin Chest Hospital

Who can join

Adults 18 to 75, any sex, with NSCLC With COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial aims to evaluate the efficacy and safety of pembrolizumab in the first-line treatment of advanced NSCLC complicated with COPD and its influence on the course of COPD, so as to provide prospective clinical evidence for immunotherapy of NSCLC complicated with COPD in China and to guide clinical application.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.
Lee D, Cho M, Kim E, Seo Y, et al · · 2024 · cited 52× · PMID 39342430 · DOI 10.1016/j.ymthe.2024.09.026
Comorbidities in COPD: Current and Future Treatment Challenges.
Mariniello DF, D'Agnano V, Cennamo D, Conte S, et al · · 2024 · cited 27× · PMID 38337438 · DOI 10.3390/jcm13030743
Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial.
Dong W, Yin Y, Liu B, Jiang Y, et al · · 2024 · cited 3× · PMID 38515570 · DOI 10.3389/fonc.2024.1179232

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other Tianjin Chest Hospital trials

Trials by the same sponsor.

NCT07063147 — TTE Improves Clinical Management of Stable Chest Pain · recruiting
NCT05640752 — Optimal Evaluation to Reduce Cardiovascular Imaging Testing · NA · recruiting
NCT04100434 — Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in P · Phase 4 · unknown
NCT03600259 — Tianjin Inpatient Acute Myocardial Infarction Registry · unknown
NCT03429192 — A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05578222 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Chest Hospital
Last refreshed: 13 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05578222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing